ArticleThe Journal of clinical endocrinology and metabolism2024
Health Care Challenges in the Management of Primary Aldosteronism in Southeast Asia.
Article in The Journal of clinical endocrinology and metabolism, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Tools to Predict Unilateral Primary Aldosteronism and Optimise Patient Selection for Adrenal Vein Sampling: A Systematic Review.Clinical endocrinology · 2025Pooled it
- Prevalence and clinical correlates of positive aldosterone-to-renin ratio screening in obese hypertensive patients with obstructive sleep apnea: a Southeast Asian cross-sectional study.Journal of human hypertension · 2026Article
- The impact of setting up an endocrine hypertension clinic at a tertiary care hospital in Bangladesh.Journal of human hypertension · 2026Article
- Aldosterone-targeted Therapy after Primary Aldosteronism Testing in Resistant Hypertension: A Nationwide Cohort Study.medRxiv : the preprint server for health sciences · 2026Article
- Renin-aldosterone testing: The essentials.Clinical medicine (London, England) · 2026Review
- Is It Time to Retire Aldosterone Suppression Testing?American journal of hypertension · 2026Review
- Incidence of Adrenal Masses Eventually Discovered in Patients Screened for Primary Aldosteronism.The Journal of clinical endocrinology and metabolism · 2026Article
- Primary aldosteronism beyond laterality: integrating subtype assignment with outcome-oriented risk stratification.Frontiers in endocrinology · 2026Review
- Primary aldosteronism in South Asia: insights from a tertiary outpatient cohort in Bangladesh.Endocrine connections · 2026Article
- Approach to the Patient With Primary Aldosteronism: Role of Molecular Imaging.The Journal of clinical endocrinology and metabolism · 2025Review
- Identifying unilateral aldosterone-producing adenomas using published algorithms and imaging: a systematic review and meta-analysis.Endocrine connections · 2025Article
- A global real-world study assessing total time to adrenalectomy in primary aldosteronism.European journal of endocrinology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
contextWhile guidelines have been formulated for the management of primary aldosteronism (PA), following these recommendations may be challenging in developing countries with limited health care access.
objectiveWe aimed to assess the availability and affordability of health care resources for managing PA in the Association of Southeast Asian Nations (ASEAN) region, which includes low-middle-income countries.
methodsWe instituted a questionnaire-based survey to specialists managing PA, assessing the availability and affordability of investigations and treatment. Population and income status data were taken from the national census and registries.
resultsNine ASEAN country members (48 respondents) participated. While screening with aldosterone-renin ratio is performed in all countries, confirmatory testing is routinely performed in only 6 countries due to lack of facilities and local assays, and cost constraint. Assays are locally available in only 4 countries, and some centers have a test turnaround time exceeding 3 weeks. In 7 countries (combined population of 442 million), adrenal vein sampling (AVS) is not routinely performed due to insufficient radiological facilities or trained personnel, and cost constraint. Most patients have access to adrenalectomy and medications. In 6 countries, the cost of AVS and adrenalectomy combined is more than 30% of its annual gross domestic product per capita. While most patients had access to spironolactone, it was not universally affordable.
conclusionLarge populations currently do not have access to the health care resources required for the optimal management of PA. Greater efforts are required to improve health care access and affordability. Future guideline revisions for PA may need to consider these limitations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.